Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q2 2025 · 10-Q
Revenue$11.14B$11.14B+7.4% vs Q2 2024 Net Income$1.78B$1.78B+36.6% vs Q2 2024 EPS Diluted$1.01$1.01+36.5% vs Q2 2024 Operating Income$2,052,000,000+22.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$1,545,000,000+8.3% Margins · derivedOperating margin18.4%+2.3 pt vs Q2 2024
Net margin16.0%+3.4 pt vs Q2 2024
ended Jun 30, 2025 · filed Jul 30, 2025 · 30 d after period end